Investors of Aquestive Therapeutics Urged to Join Securities Fraud Class Action Lawsuit

Urgent Notice for Investors in Aquestive Therapeutics

The Rosen Law Firm has issued an important reminder for individuals who purchased securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) from June 16, 2025, to January 8, 2026. This alert emphasizes the imminent deadline of May 4, 2026, for those interested in stepping forward as lead plaintiffs in a class action lawsuit aimed at addressing alleged securities fraud.

What You Should Know

If you bought shares during the specified period, you may qualify for compensation without the necessity of upfront legal fees, thanks to a contingency fee arrangement offered by the firm. This means that affected investors can seek legal recourse without financial risk, leading to possible recovery of losses attributed to misleading statements from the company regarding their New Drug Application (NDA) for Anaphylm.

Moreover, this class action suit stems from claims that Aquestive Therapeutics failed to accurately communicate significant factors related to the use and deployment of its sublingual film, thereby impacting investor decisions adversely. When the truth about the company's disclosures came to light, shareholders experienced material losses.

Taking the Next Steps

To join this class action lawsuit and potentially assume the role of lead plaintiff, investors are encouraged to visit Rosen Law Firm's website or contact Phillip Kim, Esq. via phone or email for guidance. It is crucial to note that until a class is certified, your interests as an investor are not formally represented unless you choose to engage a lawyer.

Rosen Law Firm emphasizes the importance of selecting legal representation based on proven success in handling securities class actions. Many firms make claims about their expertise but lack the practical experience or substantial background in this specialized area of law. This firm stands out for its track record, having achieved some of the largest settlements in securities fraud cases, highlighting its ability to advocate effectively for its clients.

Rosen Law Firm’s Credibility

With a global footprint and significant resources dedicated to securities class actions, the Rosen Law Firm has established itself as a leader in investor rights. The firm proudly claims a history of securing favorable outcomes, including a notable settlement exceeding $438 million in 2019 alone. Laurence Rosen, the founding partner, has garnered recognition in the legal community, making the firm a trustworthy choice for investors navigating complex litigations.

Additionally, the firm has been awarded top rankings by ISS Securities Class Action Services for years, further cementing its reputation within the sector.

Conclusion

For investors who have suffered losses related to Aquestive Therapeutics during the designated class period, now is the time to act. Joining the class action lawsuit offers an opportunity to seek justice and potentially recuperate lost funds. For more information on how to get involved, reach out to The Rosen Law Firm today.

Stay updated with the latest developments by following them on social media platforms like LinkedIn, Twitter, and Facebook.

This is a call to action for all impacted investors; don't miss the chance to contribute to this significant legal endeavor which could change the course for many shareholders affected by the alleged misrepresentation and fraud.

Attorney Advertising. Past results do not guarantee similar outcomes.

For inquiries, please contact:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel (212) 686-1060
Toll Free (866) 767-3653
Email: [email protected]